Spot and Tubular data show prescription immunology brands continued to dominate TV, while seasonal OTC brands found scale on ...
So first, let's consider Viking's story so far. The company is working on a dual GLP-1/GIP receptor agonist in injectable and oral formats. Injectable VK2735 is involved in a phase 3 trial right now, ...
Nine states have been pursuing the idea of prescription drug affordability boards. Maryland's board just set limits on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results